Bots, editor, reviewer, Administrators
13,951
edits
Feed:Recent Updates: Difference between revisions
Jump to navigation
Jump to search
no edit summary
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==August 2022== | ==August 2022== | ||
; [[TICORA]]: New summary # | ; [[TICORA]]: New summary #463: Intensive vs. standard treatment in early RA | ||
==July 2022== | ==July 2022== | ||
; [[NAVIGATE ESUS]]: New summary # | ; [[NAVIGATE ESUS]]: New summary #462: Rivaroxaban vs. ASA for ESUS (stroke) | ||
; [[NACSTOP]]: New summary # | ; [[NACSTOP]]: New summary #461: 12 vs. 20 hours of NAC in APAP overdose | ||
==June 2022== | ==June 2022== | ||
; [[CRB-401]]: New summary # | ; [[CRB-401]]: New summary #460: Ide-cel CART in myeloma | ||
==May 2022== | ==May 2022== | ||
| Line 15: | Line 15: | ||
==April 2022== | ==April 2022== | ||
; [[MERINO]]: New summary # | ; [[MERINO]]: New summary #459: Piperacillin-tazobactam for ESBL bacteremia | ||
==March 2022== | ==March 2022== | ||
; [[WARSS]]: New summary # | ; [[WARSS]]: New summary #458: Aspirin vs. warfarin in ischemic stroke | ||
; [[RITUXVAS]]: New summary # | ; [[RITUXVAS]]: New summary #457: Rituximab in ANCA-Renal Vasculitis | ||
==February 2022== | ==February 2022== | ||
| Line 35: | Line 35: | ||
==November 2021== | ==November 2021== | ||
; [[STEP]]: New summary # | ; [[STEP]]: New summary #456: Intensive BP control hypertension | ||
; [[ASPEN]]: New summary # | ; [[ASPEN]]: New summary #455: Zanubrutinib vs. ibrutinib in WM | ||
==October 2021== | ==October 2021== | ||
; [[EARLY-AF]]: New summary # | ; [[EARLY-AF]]: New summary #454: Cryoablation vs. antiarrhythmics in AF | ||
; [[MASTER DAPT]]: New summary # | ; [[MASTER DAPT]]: New summary #453: Abbreviated DAPT in high-risk bleeding | ||
; [[EARLY AF]]: New summary # | ; [[EARLY AF]]: New summary #452: Cryoablation vs. antiarrhythmics in AF | ||
==September 2021== | ==September 2021== | ||
; [[ANTLER]]: New summary # | ; [[ANTLER]]: New summary #451: Maintenance vs. discontinuation of antidepressants | ||
; [[DELIRIA-J]]: New summary # | ; [[DELIRIA-J]]: New summary #450: Ramelteon vs. placebo to prevent delirium | ||
; [[EMPEROR-Preserved]]: New summary # | ; [[EMPEROR-Preserved]]: New summary #449: Empagliflozin in HFmrEF and HFpEF | ||
==August 2021== | ==August 2021== | ||
; [[HORIZON-PFT]]: New summary # | ; [[HORIZON-PFT]]: New summary #448: Zoledronate vs. placebo in osteoporosis | ||
; [[65 Trial]]: New summary # | ; [[65 Trial]]: New summary #447: MAP 60-65 vs. usual care in vasodilatory hypotension in ICU | ||
==July 2021== | ==July 2021== | ||
; [[TTM2]]: New summary # | ; [[TTM2]]: New summary #446: 33 vs. 36°C body temperature after cardiac arrest | ||
; [[REALITY]]: New summary # | ; [[REALITY]]: New summary #445: Transfusion thresholds in MI | ||
; [[PREVAIL]]: New summary # | ; [[PREVAIL]]: New summary #444: LAA closure vs. warfarin in AF | ||
==June 2021== | ==June 2021== | ||
; [[MRFIT]]: New summary # | ; [[MRFIT]]: New summary #443: CHD risk modification for CHD mortality prevention | ||
==May 2021== | ==May 2021== | ||
; [[PERC]]: New summary # | ; [[PERC]]: New summary #442: PE rule-out criteria | ||
; [[Novel START]]: New summary # | ; [[Novel START]]: New summary #441: ICS+LABA PRN in mild asthma | ||
==April 2021== | ==April 2021== | ||
; [[PAUSE]]: New summary # | ; [[PAUSE]]: New summary #440: Perioperative DOAC holding protocols in AF | ||
; [[STEP 1]]: New summary # | ; [[STEP 1]]: New summary #439: Semaglutide in obesity without diabetes | ||
==March 2021== | ==March 2021== | ||
; [[How Long]]: New summary # | ; [[How Long]]: New summary #438: Duration of empiric antibiotics in ↑risk neutropenic fever | ||
; [[APROCCHSS]]: New summary # | ; [[APROCCHSS]]: New summary #437: Steroids in septic shock | ||
==February 2021== | ==February 2021== | ||
; [[LoDoCo2]]: New summary # | ; [[LoDoCo2]]: New summary #436: Colchicine in stable CAD | ||
; [[PATHWAY-2]]: New summary # | ; [[PATHWAY-2]]: New summary #435: Spironolactone for resistant HTN | ||
==January 2021== | ==January 2021== | ||
; [[EAST-AFNET 4]]: New summary # | ; [[EAST-AFNET 4]]: New summary #434: Early rhythm vs. rate control in AF | ||
; [[ISCHEMIA]]: New summary # | ; [[ISCHEMIA]]: New summary #433: PCI/CABG vs. medical therapy in stable CAD | ||
; [[PRAETORIAN]]: New summary # | ; [[PRAETORIAN]]: New summary #432: Transvenous vs. subq ICD to prevent sudden cardiac death | ||
==December 2020== | ==December 2020== | ||
; [[SUSTAIN]]: New summary # | ; [[SUSTAIN]]: New summary #431: Crizanlizumab vs. placebo in SCD | ||
; [[MIST2]]: New summary # | ; [[MIST2]]: New summary #430: tPA and/or DNase for pleural infection | ||
; [[HOPE (Sickle Cell Disease)]]: New summary # | ; [[HOPE (Sickle Cell Disease)]]: New summary #429: Voxelotor in sickle cell disease | ||
==November 2020== | ==November 2020== | ||
; [[ALLHAT-LLT Elderly]]: New summary # | ; [[ALLHAT-LLT Elderly]]: New summary #428: Pravastatin vs usual care for ASCVD primary prevention | ||
==October 2020== | ==October 2020== | ||
; [[CARAVAGGIO]]: New summary # | ; [[CARAVAGGIO]]: New summary #427: Apixaban vs. dalteparin in cancer VTE | ||
; [[DAPA-CKD]]: New summary # | ; [[DAPA-CKD]]: New summary #426: Dapagliflozin in CKD±T2DM | ||
==September 2020== | ==September 2020== | ||
; [[VITAMINS]]: New summary # | ; [[VITAMINS]]: New summary #425: Vitamin C, hydrocortisone, & thiamine in septic shock | ||
==August 2020== | ==August 2020== | ||
; [[RECOVERY (Covid-19)]]: New summary # | ; [[RECOVERY (Covid-19)]]: New summary #424: Dexamethasone vs. usual care in Covid-19 | ||
; [[B-CONVINCED]]: New summary # | ; [[B-CONVINCED]]: New summary #423: Beta-blocker withdrawal in ADHF | ||
==July 2020== | ==July 2020== | ||
; On paternity leave! Back in a couple of weeks. | ; On paternity leave! Back in a couple of weeks. | ||
; [[PARAGON-HF]]: New summary # | ; [[PARAGON-HF]]: New summary #422: ARNI in symptomatic HFpEF | ||
==June 2020== | ==June 2020== | ||
; [[AMAZES]]: New summary # | ; [[AMAZES]]: New summary #421: Azithromycin in chronic asthma | ||
; [[ACTT-1]]: New summary # | ; [[ACTT-1]]: New summary #420: Remdesivir vs. placebo in Covid-19 | ||
==May 2020== | ==May 2020== | ||
; [[SPICE III]]: New summary # | ; [[SPICE III]]: New summary #419: Dexmedetomidine in ICU sedation | ||
==March & April 2020== | ==March & April 2020== | ||
| Line 136: | Line 136: | ||
==February 2020== | ==February 2020== | ||
; [[Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia]]: New summary # | ; [[Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia]]: New summary #418: Ibrutinib-rituximab vs. FCR in untreated CLL | ||
; [[HPS Statin]]: New summary # | ; [[HPS Statin]]: New summary #417: Simvastatin in high risk for CVD | ||
==January 2020== | ==January 2020== | ||
; [[STOP-IT]]: New summary # | ; [[STOP-IT]]: New summary #416: Duration of abx in intraabdominal infection | ||
; [[DAWN]]: New summary # | ; [[DAWN]]: New summary #415: Thrombectomy 6-24 hours after stroke | ||
==December 2019== | ==December 2019== | ||
; On paternity leave!: Back in January 2020. | ; On paternity leave!: Back in January 2020. | ||
; [[DAPA-HF]]: New summary # | ; [[DAPA-HF]]: New summary #414: Dapagliflozin in HFrEF | ||
==November 2019== | ==November 2019== | ||
; [[COLCOT]]: New summary # | ; [[COLCOT]]: New summary #413: Colchicine vs. placebo in ACS | ||
; [[CORAL]]: New summary # | ; [[CORAL]]: New summary #412: Stenting vs. medical therapy in RAS | ||
==October 2019== | ==October 2019== | ||
; [[PARTNER 3]]: New summary # | ; [[PARTNER 3]]: New summary #411: TAVR for AS in low-risk surgical candidates | ||
; [[AUGUSTUS]]: New summary # | ; [[AUGUSTUS]]: New summary #410: DOAC, VKA, antiplatelets after PCI with stent and AF | ||
; [[ISAR-REACT 5]]: New summary # | ; [[ISAR-REACT 5]]: New summary #409: Ticagrelor vs. prasugrel in ACS | ||
==September 2019== | ==September 2019== | ||
; [[HOPE-3]]: New summary # | ; [[HOPE-3]]: New summary #408: Statin, BP meds, both, or neither for CVD 1° prevention | ||
; [[EASE]]: New summary # | ; [[EASE]]: New summary #407: Early surgery in endocarditis | ||
; [[S-HYDRACYST]]: New summary # | ; [[S-HYDRACYST]]: New summary #406: Increasing water intake to prevent UTIs in premenopausal women | ||
; [[3C]]: New summary # | ; [[3C]]: New summary #405: Antibiotic strategies in lower respiratory tract infections | ||
==August 2019== | ==August 2019== | ||
; [[RAMPART]]: New summary # | ; [[RAMPART]]: New summary #404: Midazolam vs. lorazepam for status epilepticus | ||
; [[AASK]]: New summary # | ; [[AASK]]: New summary #403: BP management for CKD in African Americans | ||
==July 2019== | ==July 2019== | ||
; [[CREDENCE]]: New summary # | ; [[CREDENCE]]: New summary #402: Canagliflozin in diabetic nephropathy | ||
; [[ARREST]]: New summary # | ; [[ARREST]]: New summary #401: Rifampin in S. aureus bacteremia | ||
; [[DODS]]: New summary # | ; [[DODS]]: New summary #400: D-dimer based anticoagulation discontinuation | ||
==June 2019== | ==June 2019== | ||
; [[WASID]]: New summary # | ; [[WASID]]: New summary #399: Warfarin vs. aspirin for intracranial atherosclerosis | ||
; [[SPACE]]: New summary # | ; [[SPACE]]: New summary #398: Opioids vs. non-opioids in chronic MSK pain | ||
; [[TRED-HF]]: New summary # | ; [[TRED-HF]]: New summary #397: Withdrawal of medications in dilated cardiomyopathy | ||
; [[TIPPS]]: New summary # | ; [[TIPPS]]: New summary #396: Dalteparin in pregnant woman with thrombophilias | ||
; [[ROSE]]: New summary # | ; [[ROSE]]: New summary #395: Cisatracurium NM blockade in ARDS | ||
==May 2019== | ==May 2019== | ||
; [[IALT]]: New summary # | ; [[IALT]]: New summary #394: Adjuvant cisplatin in resected NSCLC | ||
; [[ASPREE]]: New summary # | ; [[ASPREE]]: New summary #393: Aspirin for ASCVD 1° prevention if age >70 | ||
; [[DONATE-HCV]]: New summary # | ; [[DONATE-HCV]]: New summary #392: Donor HCV positive heart and lung transplant | ||
==April 2019== | ==April 2019== | ||
; [[REMATCH]]: New summary # | ; [[REMATCH]]: New summary #391: Destination LVAD in end-stage heart failure | ||
; [[OVIVA]]: New summary # | ; [[OVIVA]]: New summary #390: PO vs. IV antibiotics for bone/joint infection | ||
; [[POET]]: New summary # | ; [[POET]]: New summary #389: PO abx after 10d IV abx for left-sided endocarditis | ||
; [[CABANA]]: New summary # | ; [[CABANA]]: New summary #388: Catheter ablation vs. anti-arrhythmic therapy in AF | ||
==March 2019== | ==March 2019== | ||
; [[CASSINI]]: New summary # | ; [[CASSINI]]: New summary #387: Rivaroxaban for VTE prevention in cancer | ||
; [[CAPRICORN]]: New summary # | ; [[CAPRICORN]]: New summary #386: Carvedilol post-MI with HFrEF | ||
; [[IDEAL-ICU]]: New summary # | ; [[IDEAL-ICU]]: New summary #385: Early vs. delayed RRT in septic shock | ||
; [[FAIR-HF]]: New summary # | ; [[FAIR-HF]]: New summary #384: Parenteral iron in HFrEF with iron deficiency | ||
==February 2019== | ==February 2019== | ||
; [[BICAR-ICU]]: New summary # | ; [[BICAR-ICU]]: New summary #383: Bicarbonate in severe metabolic acidosis | ||
; [[ProMISe]]: New summary # | ; [[ProMISe]]: New summary #382: Multicenter EGDT trial in severe sepsis | ||
; [[ANNEXA-4]]: New summary # | ; [[ANNEXA-4]]: New summary #381: Andexanet alfa for factor Xa inhibitor reversal | ||
; [[ART]]: New summary # | ; [[ART]]: New summary #380: Bilateral vs. single IMA graft in multivessel CAD | ||
==January 2019== | ==January 2019== | ||
; [[PIONEER-HF]]: New summary # | ; [[PIONEER-HF]]: New summary #379: ARNI started in ADHF hospitalization | ||
; [[AVERT]]: New summary # | ; [[AVERT]]: New summary #378: Apixaban for VTE prevention in cancer | ||
==December 2018== | ==December 2018== | ||
; [[REDUCE-IT]]: New summary # | ; [[REDUCE-IT]]: New summary #377: Icosapent ethyl in CAD | ||
; [[SELECT-D]]: New summary # | ; [[SELECT-D]]: New summary #376: Rivaroxaban vs. LMWH in cancer VTE | ||
; [[AURORA]]: New summary # | ; [[AURORA]]: New summary #375: Rosuvastatin in ESRD | ||
; [[COAPT]]: New summary # | ; [[COAPT]]: New summary #374: Mitra Clip for HF-related MR | ||
; [[AF-CHF]]: New summary # | ; [[AF-CHF]]: New summary #373: Rhythm control for AF in HFrEF | ||
==November 2018== | ==November 2018== | ||
; [[MIND-USA]]: New summary # | ; [[MIND-USA]]: New summary #372: Antipsychotics in ICU delirium | ||
; [[CIRT]]: New summary # | ; [[CIRT]]: New summary #371: Low-dose MTX for secondary prevention of CAD | ||
; [[DIVA]]: New summary # | ; [[DIVA]]: New summary #370: BMS vs. DES for saphenous vein graft PCI | ||
; [[APEX]]: New summary # | ; [[APEX]]: New summary #369: Betrixaban for extended VTE prophylaxis | ||
; [[SUP-ICU]]: New summary # | ; [[SUP-ICU]]: New summary #368: Routine PPI use in the ICU | ||
==October 2018== | ==October 2018== | ||
; [[VEST]]: New summary # | ; [[VEST]]: New summary #367: Wearable cardioverter-defibrillator post-MI | ||
; [[Radiograph vs. MRI for low back pain]]: New summary # | ; [[Radiograph vs. MRI for low back pain]]: New summary #366: Radiograph vs. MRI for low back pain | ||
; [[LenDex in High-Risk Smoldering Myeloma]]: New summary # | ; [[LenDex in High-Risk Smoldering Myeloma]]: New summary #365: Lenalidomide/dexamethasone in smoldering MM | ||
; [[TRAPS]]: New summary # | ; [[TRAPS]]: New summary #364: Rivaroxaban in high-risk APLS | ||
==September 2018== | ==September 2018== | ||
; [[MARINER]]: New summary # | ; [[MARINER]]: New summary #363: Rivaroxaban VTE ppx after medical admission | ||
; [[EMBRACE]]: New summary # | ; [[EMBRACE]]: New summary #362: Extended EKG monitoring after cryptogenic stroke | ||
; [[ATTR-ACT]]: New summary # | ; [[ATTR-ACT]]: New summary #361: Tafamidis vs. placebo in amyloid cardiomyopathy | ||
; [[ASCEND (Aspirin)]]: New summary # | ; [[ASCEND (Aspirin)]]: New summary #360: Aspirin for vascular disease prevention in DM | ||
; [[ACOSOG Z0011]]: New summary # | ; [[ACOSOG Z0011]]: New summary #359: ALND in SLND-positive breast cancer | ||
==August 2018== | ==August 2018== | ||
; [[SOME]]: New summary # | ; [[SOME]]: New summary #358: Occult cancer screening in unprovoked VTE | ||
; [[Early TIPS]]: New summary # | ; [[Early TIPS]]: New summary #357: Early TIPS in high-risk cirrhotic variceal bleeding | ||
; [[Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock]]: New summary # | ; [[Hydrocortisone, Vitamin C, and Thiamine in Severe Sepsis and Septic Shock]]: New summary #356: Hydrocortisone, Vit C, and thiamine in sepsis | ||
; [[POINT]]: New summary # | ; [[POINT]]: New summary #355: Aspirin/clopidogrel vs. aspirin in stroke/TIA | ||
==July 2018== | ==July 2018== | ||
; [[APPAC]]: New summary # | ; [[APPAC]]: New summary #354: Antibiotics vs. surgery for acute appendicitis | ||
; [[RESCUEicp]]: New summary # | ; [[RESCUEicp]]: New summary #353: Craniectomy vs. medical care for intracranial hypertension | ||
; [[ATTRACT]]: New summary # | ; [[ATTRACT]]: New summary #352: Pharmacomechanical therapy vs. anticoagulation in DVT | ||
; Welcome new medical students, interns, residents, and fellows!: Buckle in for a year to remember. We hope Journal Club makes it a touch easier. You got this! | ; Welcome new medical students, interns, residents, and fellows!: Buckle in for a year to remember. We hope Journal Club makes it a touch easier. You got this! | ||
==June 2018== | ==June 2018== | ||
; [[MOMENTUM 3]]: New summary # | ; [[MOMENTUM 3]]: New summary #351: Centrifugal-flow LVAD vs. axial-flow LVAD in advanced HF | ||
; [[SPYRAL HTN-ON MED]]: New summary # | ; [[SPYRAL HTN-ON MED]]: New summary #350: Renal denervation in resistant hypertension | ||
; [[RABBIT 2]]: New summary # | ; [[RABBIT 2]]: New summary #349: Basal-bolus insulin in inpatients with DM | ||
; [[PREDIMED]]: We incorporated our thoughts on the retraction and replacement of this high-impact NEJM trial on the Mediterranean diet for prevention of CVD. | ; [[PREDIMED]]: We incorporated our thoughts on the retraction and replacement of this high-impact NEJM trial on the Mediterranean diet for prevention of CVD. | ||
==May 2018== | ==May 2018== | ||
; [[TIMACS]]: New summary # | ; [[TIMACS]]: New summary #348: Early vs. delayed PCI in NSTEMI and UA | ||
; [[DPP]]: New summary # | ; [[DPP]]: New summary #347: Metformin and intensive lifestyle in prediabetes | ||
; [[DANAMI-3 PRIMULTI]]: New summary # | ; [[DANAMI-3 PRIMULTI]]: New summary #346: Culprit lesion PCI vs. FFR in multivessel CAD | ||
==April 2018== | ==April 2018== | ||
; [[OASIS-5]]: New summary # | ; [[OASIS-5]]: New summary #345: Fondaparinux vs. enoxaparin in NSTE-ACS | ||
; [[TRICS III]]: New summary # | ; [[TRICS III]]: New summary #344: Transfusion thresholds for cardiac surgery | ||
; [[SMART-MED and SMART-SURG]]: New summary # | ; [[SMART-MED and SMART-SURG]]: New summary #343: NS vs. balanced crystalloids in ICU | ||
; [[SALT-ED]]: New summary # | ; [[SALT-ED]]: New summary #342: Balanced crystalloids vs. NS in non-critical ED patients | ||
; [[Blood Pressure Reduction in Black Barbershops]]: New summary # | ; [[Blood Pressure Reduction in Black Barbershops]]: New summary #341: PharmD-guided BP reduction for black men in barbershops | ||
==March 2018== | ==March 2018== | ||
; [[INPULSIS Trials]]: New summary # | ; [[INPULSIS Trials]]: New summary #340: Nintedanib in IPF | ||
; [[EPCAT II]]: New summary # | ; [[EPCAT II]]: New summary #339: Aspirin vs. rivaroxaban for postoperative VTE prophylaxis | ||
; [[HEMO]]: New summary # | ; [[HEMO]]: New summary #338: High dialysis dose and high-flux membrane in hemodialysis | ||
; [[Compare-Acute]]: New summary # | ; [[Compare-Acute]]: New summary #337: Multivessel PCI vs. FFR-guided complete revascularization | ||
; [[CAP-START]]: New summary # | ; [[CAP-START]]: New summary #336: Antibiotic strategies for PNA | ||
==February 2018== | ==February 2018== | ||
; [[Hokusai-VTE]]: New summary # | ; [[Hokusai-VTE]]: New summary #335: Edoxaban vs. LMWH in cancer VTE | ||
; [[EUROPA]]: New summary # | ; [[EUROPA]]: New summary #334: Perindopril in patients with stable CAD | ||
; [[CASTLE-AF]]: New summary # | ; [[CASTLE-AF]]: New summary #333: Catheter ablation vs. standard therapy in AF+HF | ||
; [[ADRENAL]]: New summary # | ; [[ADRENAL]]: New summary #332: Hydrocortisone in septic shock | ||
; [[Hokusai VTE Cancer Trial]]: New summary # | ; [[Hokusai VTE Cancer Trial]]: New summary #331: Edoxaban vs. LMWH in cancer VTE | ||
==January 2018== | ==January 2018== | ||
; [[RE-DUAL]]: New summary # | ; [[RE-DUAL]]: New summary #330: Triple therapy vs. ASA+dabigatran in PCI if AF | ||
; [[PROTECT AF]]: New summary # | ; [[PROTECT AF]]: New summary #329: LAA closure vs. warfarin in AF | ||
; [[ACCORD Lipid]]: New summary # | ; [[ACCORD Lipid]]: New summary #328: Fibrate add-on to statins in T2DM | ||
==December 2017== | ==December 2017== | ||
; [[TONE]]: New summary # | ; [[TONE]]: New summary #327: Na reduction and weight loss for HTN control in elderly | ||
; [[ORBITA]]: New summary # | ; [[ORBITA]]: New summary #326: PCI vs. medical therapy in stable angina | ||
; [[FOCUS]]: New summary # | ; [[FOCUS]]: New summary #325: Transfusion thresholds after hip surgery | ||
==November 2017== | ==November 2017== | ||
; [[CAMERA]]: New summary # | ; [[CAMERA]]: New summary #324: Methotrexate strategies in RA | ||
; [[ALMS]]: New summary # | ; [[ALMS]]: New summary #323: MMF vs. CTX in lupus nephritis | ||
; [[CULPRIT-SHOCK]]: New summary # | ; [[CULPRIT-SHOCK]]: New summary #322: Culprit-only vs. multivessel PCI in cardiogenic shock | ||
; [[V-HeFT II]]: New summary # | ; [[V-HeFT II]]: New summary #321: Enalapril vs. ISDN/hydralazine in HFrEF | ||
==October 2017== | ==October 2017== | ||
; [[DETO2X-AMI]]: New summary # | ; [[DETO2X-AMI]]: New summary #320: Oxygen for suspected MI | ||
; [[RELAX]]: New summary # | ; [[RELAX]]: New summary #319: Sildenafil vs. placebo in HFpEF | ||
; [[PROLONG]]: New summary # | ; [[PROLONG]]: New summary #318: D-Dimer testing after VTE | ||
; [[CANTOS]]: New summary # | ; [[CANTOS]]: New summary #317: Canakinumab in patients with previous MI | ||
==September 2017== | ==September 2017== | ||
; [[POP-UP]]: New summary # | ; [[POP-UP]]: New summary #316: PPIs for stress ulcer prophylaxis | ||
; [[Albumin for SBP]]: New summary # | ; [[Albumin for SBP]]: New summary #315: Albumin for SBP in cirrhosis | ||
; [[COMPASS]]: New summary # | ; [[COMPASS]]: New summary #314: Rivaroxaban, ASA, or both in stable CAD | ||
; [[HEAT]]: New summary # | ; [[HEAT]]: New summary #313: Acetaminophen in febrile ICU patients | ||
; [[AVOID]]: New summary # | ; [[AVOID]]: New summary #312: Supplemental oxygen in STEMI | ||
==August 2017== | ==August 2017== | ||
; [[CANVAS]]: New summary # | ; [[CANVAS]]: New summary #311: Canagliflozin for CV outcomes in T2DM | ||
; [[TRIUMPH]]: New summary # | ; [[TRIUMPH]]: New summary #310: Eculizumab in PNH | ||
; [[AKIKI]]: New summary # | ; [[AKIKI]]: New summary #309: Early vs. late RRT in severe AKI in ICU | ||
; [[ATHOS-3]]: New summary # | ; [[ATHOS-3]]: New summary #308: Angiotensin II vs. placebo in vasodilatory shock | ||
==July 2017== | ==July 2017== | ||
; Welcome new medical students, interns, residents, and fellows! : This is going to be a tough but great year. We hope Journal Club makes it a touch easier for you. | ; Welcome new medical students, interns, residents, and fellows! : This is going to be a tough but great year. We hope Journal Club makes it a touch easier for you. | ||
; [[IRONOUT-HF]]: New summary # | ; [[IRONOUT-HF]]: New summary #307: Oral iron vs. placebo in HFrEF and iron deficiency | ||
; [[EINSTEIN CHOICE]]: New summary # | ; [[EINSTEIN CHOICE]]: New summary #306: Rivaroxaban after VTE treatment | ||
==June 2017== | ==June 2017== | ||
; [[AIDA]]: New summary # | ; [[AIDA]]: New summary #305: Scaffold vs. stent in PCI | ||
; [[BLOCK-HF]]: New summary # | ; [[BLOCK-HF]]: New summary #304: RV pacing vs. BiV pacing in HF with AV block | ||
; [[CHAMPION PHOENIX]]: New summary # | ; [[CHAMPION PHOENIX]]: New summary #303: Cangrelor during urgent or elective PCI | ||
==May 2017== | ==May 2017== | ||
; [[IFR-SWEDEHEART]]: New summary # | ; [[IFR-SWEDEHEART]]: New summary #302: iFR vs. FFR for PCI | ||
; [[MODIFY I and II]]: New summary # | ; [[MODIFY I and II]]: New summary #301: Bezlotoxumab for the prevention of recurrent Clostridium difficile Infection | ||
; [[BEST]]: New summary # | ; [[BEST]]: New summary #300: PCI vs. CABG for multivessel disease | ||
==April 2017== | ==April 2017== | ||
; [[Cranberry for prevention of pyuria and bacteriuria]]: New summary # | ; [[Cranberry for prevention of pyuria and bacteriuria]]: New summary #299: Cranberry in for prevention of pyuria and bacteriuria | ||
; [[SURTAVI]]: New summary # | ; [[SURTAVI]]: New summary #298: TAVI for AS in intermediate-risk surgical candidates | ||
==March 2017== | ==March 2017== | ||
; [[ANNEXA]]: New summary # | ; [[ANNEXA]]: New summary #297: Andexanet for reversing Xa inhibitors | ||
; [[FOURIER]]: New summary # | ; [[FOURIER]]: New summary #296: Evolocumab for CVD events if atherosclerotic disease | ||
; [[PRECISION]]: New summary # | ; [[PRECISION]]: New summary #295: Celecoxib, naproxen, or ibuprofen for CV safety in arthritis | ||
==February 2017== | ==February 2017== | ||
; [[ENGAGE AF-TIMI 48]]: New summary # | ; [[ENGAGE AF-TIMI 48]]: New summary #294: Edoxaban vs. warfarin in AF | ||
; [[CvLPRIT]]: New summary # | ; [[CvLPRIT]]: New summary #293: Culprit lesion-only vs. complete revascularization | ||
==January 2017== | ==January 2017== | ||
; [[FLAME (COPD)]]: New summary # | ; [[FLAME (COPD)]]: New summary #292: LABA+LAMA vs. LABA+ICS in COPD | ||
; Updated Surviving Sepsis guidelines: [[Daily ICU Sedation Holidays]], [[ATN]], [[ARDSNet]], [[ACURASYS]], [[PROSEVA]], [[OSCILLATE]], [[Leuven Surgical Trial]], [[NICE-SUGAR]], [[PRORATA]], [[TRICC]], [[ALBIOS]], [[SAFE]], [[CRISTAL]], [[VASST]], [[SOAP II]], [[SEPSISPAM]], [[CORTICUS]], [[Annane Trial]], [[ProMISe]], [[ARISE]], [[ProCESS]], [[Rivers Trial]] | ; Updated Surviving Sepsis guidelines: [[Daily ICU Sedation Holidays]], [[ATN]], [[ARDSNet]], [[ACURASYS]], [[PROSEVA]], [[OSCILLATE]], [[Leuven Surgical Trial]], [[NICE-SUGAR]], [[PRORATA]], [[TRICC]], [[ALBIOS]], [[SAFE]], [[CRISTAL]], [[VASST]], [[SOAP II]], [[SEPSISPAM]], [[CORTICUS]], [[Annane Trial]], [[ProMISe]], [[ARISE]], [[ProCESS]], [[Rivers Trial]] | ||
; [[EUCLID (Ticagrelor)]]: New summary # | ; [[EUCLID (Ticagrelor)]]: New summary #291: Ticagrelor vs. clopidogrel in symptomatic PAD | ||
==December 2016== | ==December 2016== | ||
; [[MUSTT]]: New summary # | ; [[MUSTT]]: New summary #290: ICD vs. antiarrhythmics vs. neither in mild HF and VT at EPS | ||
; [[EXCEL]]: New summary # | ; [[EXCEL]]: New summary #289: CABG vs. PCI in left main CAD | ||
; [[PIONEER AF-PCI]]: New summary # | ; [[PIONEER AF-PCI]]: New summary #288: DOAC, VKA, antiplatelets after PCI with stent | ||
; [[AIRTRIP]]: New summary # | ; [[AIRTRIP]]: New summary #287: Anakinra in colchicine-resistant pericarditis | ||
==November 2016== | ==November 2016== | ||
; [[PESIT]]: New summary # | ; [[PESIT]]: New summary #286: Prevalence of PE in syncope | ||
; [[KEYNOTE-024]]: New summary # | ; [[KEYNOTE-024]]: New summary #285: Pembrolizumab vs. chemotherapy in NSCLC | ||
; [[HYPRESS]]: New summary # | ; [[HYPRESS]]: New summary #284: Hydrocortisone in severe sepsis | ||
==October 2016== | ==October 2016== | ||
; [[NORSTENT]]: New summary # | ; [[NORSTENT]]: New summary #283: Drug-eluting stent vs. bare-metal stent in CAD | ||
; [[ISAR-TRIPLE]]: New summary # | ; [[ISAR-TRIPLE]]: New summary #282: Triple therapy for 6w vs. 6m after DES | ||
; [[SOCRATES]]: New summary # | ; [[SOCRATES]]: New summary #281: Ticagrelor vs. aspirin in acute stroke or TIA | ||
==September 2016== | ==September 2016== | ||
| Line 466: | Line 466: | ||
: '''Benjamin A. Weinberg, MD''' from Georgetown/Lombardi Cancer Center and '''Nirmal Choradia, MD''' from Georgetown/MedStar Montgomery Medical Center. Are you interested in becoming a WJC editor? [http://bit.ly/1JMUsAb Read more about the editorial positions.] | : '''Benjamin A. Weinberg, MD''' from Georgetown/Lombardi Cancer Center and '''Nirmal Choradia, MD''' from Georgetown/MedStar Montgomery Medical Center. Are you interested in becoming a WJC editor? [http://bit.ly/1JMUsAb Read more about the editorial positions.] | ||
; [[AATAC]]: New summary # | ; [[AATAC]]: New summary #280: AF ablation vs. amiodarone in HFrEF with LVEF ≤40% | ||
; [[DANISH]]: New summary # | ; [[DANISH]]: New summary #279: ICD vs. standard care in NICM and LVEF ≤35% | ||
; [[LEADER]]: New summary # | ; [[LEADER]]: New summary #278: Liraglutide and CVD endpoints in T2DM | ||
; [[RAFT]]: New summary # | ; [[RAFT]]: New summary #277: CRT+ICD for mild-moderate HFrEF | ||
; [[PRODIGE 4 ACCORD 11]]: New summary # | ; [[PRODIGE 4 ACCORD 11]]: New summary #276: FOLFIRINOX in pancreatic cancer | ||
; [[HEARTMATE II]]: New summary # | ; [[HEARTMATE II]]: New summary #275: Continuous-flow LVAD in heart failure | ||
==August 2016== | ==August 2016== | ||
; [[MPACT]]: New summary # | ; [[MPACT]]: New summary #274: Gemcitabine/nab-paclitaxel in pancreatic cancer | ||
; [[SPAF]]: New summary # | ; [[SPAF]]: New summary #273: Aspirin and warfarin in AF | ||
; [[DAVID]]: New summary # | ; [[DAVID]]: New summary #272: Dual-chamber vs. ventricular backup pacing in ICD patients | ||
==July 2016== | ==July 2016== | ||
; Welcome, new medical students, interns, residents, and fellows! | ; Welcome, new medical students, interns, residents, and fellows! | ||
; [[MSH]]: New summary # | ; [[MSH]]: New summary #271: Hydroxyurea in sickle-cell disease | ||
; [[ERSPC]]: New summary # | ; [[ERSPC]]: New summary #270: PSA for prostate cancer screening | ||
; [[FIRE AND ICE]]: New summary # | ; [[FIRE AND ICE]]: New summary #269: Cryoablation vs. RF ablation in pAF | ||
; [[COLONPREV]]: New summary # | ; [[COLONPREV]]: New summary #268: FIT vs. colonoscopy for colon cancer screening | ||
==June 2016== | ==June 2016== | ||
; [[VANISH]]: New summary # | ; [[VANISH]]: New summary #267: Ablation vs. antiarrhythmic drugs in VT | ||
; [[OAT]]: New summary # | ; [[OAT]]: New summary #266: PCI+OMT vs. OMT 3-28 days after MI | ||
; [[SPS3 Clopidogrel-ASA]]: New summary # | ; [[SPS3 Clopidogrel-ASA]]: New summary #265: Clopidogrel+ASA for lacunar strokes | ||
==May 2016== | ==May 2016== | ||
; [[PARTNER 2]]: New summary # | ; [[PARTNER 2]]: New summary #264: TAVI for AS in intermediate-risk surgical candidates | ||
; [[PARTNER A]]: New summary # | ; [[PARTNER A]]: New summary #263: TAVI for AS in high-risk surgical candidates | ||
; [[TACTICS-TIMI 18]]: New summary # | ; [[TACTICS-TIMI 18]]: New summary #262: Early vs. Delayed PCI for UA-NSTEMI | ||
; [[SHIFT]]: New summary # | ; [[SHIFT]]: New summary #261: Ivabradine in HFrEF | ||
==April 2016== | ==April 2016== | ||
; [[FREEDOM]]: New summary # | ; [[FREEDOM]]: New summary #260: CABG vs. PCI for CAD in T2DM | ||
; [[DINAMIT]]: New summary # | ; [[DINAMIT]]: New summary #259: ICD for ICM shortly after MI | ||
; [[NEAT-HFpEF]]: New summary # | ; [[NEAT-HFpEF]]: New summary #258: Nitrates for activity tolerance in HFpEF | ||
; [[CATIE-AD]]: New summary # | ; [[CATIE-AD]]: New summary #257: Antipsychotics in dementia with psychosis | ||
==March 2016== | ==March 2016== | ||
; [[SAMMPRIS]]: New summary # | ; [[SAMMPRIS]]: New summary #256: Stenting in intracranial stenosis | ||
; [[STOPAH]]: New summary # | ; [[STOPAH]]: New summary #255: Prednisolone vs. pentoxifylline in alcoholic hepatitis | ||
; [[PREPIC]]: New summary # | ; [[PREPIC]]: New summary #254: IVC filters for proximal DVT | ||
==February 2016== | ==February 2016== | ||
; [[CYTO-PV]]: New summary # | ; [[CYTO-PV]]: New summary #253: Hematocrit thresholds in PV | ||
; [[Benazepril in Severe CKD]]: New summary # | ; [[Benazepril in Severe CKD]]: New summary #252: Benazepril in non-diabetic CKD | ||
; 2016 Chest guidelines updated: Updates applied to [[AMPLIFY]], [[EINSTEIN-PE]], [[RE-COVER]], and other articles addressing antithrombotic therapy. | ; 2016 Chest guidelines updated: Updates applied to [[AMPLIFY]], [[EINSTEIN-PE]], [[RE-COVER]], and other articles addressing antithrombotic therapy. | ||
==January 2016== | ==January 2016== | ||
; [[RE-VERSE AD]]: New summary # | ; [[RE-VERSE AD]]: New summary #251: Idarucizumab for dabigatran reversal | ||
; [[INSIGHT START]]: New summary # | ; [[INSIGHT START]]: New summary #250: Early vs. delayed ART in HIV | ||
; [[IDNT]]: New summary # | ; [[IDNT]]: New summary #249: ARBs in diabetic nephropathy | ||
; [[SPS3-BP]]: New summary # | ; [[SPS3-BP]]: New summary #248: SBP <130 vs. SBP 130-150 after lacunar strokes | ||
==December 2015== | ==December 2015== | ||
; [[PEGASUS-TIMI 54]]: New summary # | ; [[PEGASUS-TIMI 54]]: New summary #247: Extended ticagrelor+ASA after MI | ||
; [[Ibrutinib in Waldenstrom macroglobulinemia]]: New summary # | ; [[Ibrutinib in Waldenstrom macroglobulinemia]]: New summary #246: Second-line ibrutinib in WM | ||
; [[ANRS IPERGAY]]: New summary # | ; [[ANRS IPERGAY]]: New summary #245: Pre-exposure prophylaxis in high-risk men | ||
; Welcome New Editor! | ; Welcome New Editor! | ||
| Line 555: | Line 555: | ||
==November 2015== | ==November 2015== | ||
; [[3SITES]]: New summary # | ; [[3SITES]]: New summary #244: Central line complications by insertion site | ||
; ZDoggMD! : Many thanks to [http://zdoggmd.com/ ZDoggMD] for having us as extras in his '''just released''' video, [http://zdoggmd.com/it-was-a-good-call-day/ It Was a Good Call Day]. It was an incredibly fun and funny shoot. | ; ZDoggMD! : Many thanks to [http://zdoggmd.com/ ZDoggMD] for having us as extras in his '''just released''' video, [http://zdoggmd.com/it-was-a-good-call-day/ It Was a Good Call Day]. It was an incredibly fun and funny shoot. | ||
| Line 562: | Line 562: | ||
: '''Kevin Seitz''', MD/MSc candidate at Emory University, joins us as Deputy Editor of Pulmonology/Critical Care Medicine. And '''Jun Ng''', MBBS from the University of Queensland, comes aboard as Associate Editor of Endocrinology. | : '''Kevin Seitz''', MD/MSc candidate at Emory University, joins us as Deputy Editor of Pulmonology/Critical Care Medicine. And '''Jun Ng''', MBBS from the University of Queensland, comes aboard as Associate Editor of Endocrinology. | ||
; [[SPRINT]]: New summary # | ; [[SPRINT]]: New summary #243: BP targets in high-risk patients | ||
; [[FRISC-II]]: New summary # | ; [[FRISC-II]]: New summary #242: Early invasive strategy in UA/NSTEMI | ||
==October 2015== | ==October 2015== | ||
; [[EMPA-REG OUTCOME]]: New summary # | ; [[EMPA-REG OUTCOME]]: New summary #241: Empagliflozin for CV outcomes in T2DM | ||
; [[MASS]]: New summary # | ; [[MASS]]: New summary #240: US screening for AAA in men | ||
; Updated apps!: New Journal Club apps are here for iOS and Android! Now with favorites and slick-looking reference pop-ups. Head to [http://www.journalclubapp.com journalclubapp.com] and grab it for yourself! | ; Updated apps!: New Journal Club apps are here for iOS and Android! Now with favorites and slick-looking reference pop-ups. Head to [http://www.journalclubapp.com journalclubapp.com] and grab it for yourself! | ||
; [[EVOLVE]]: New summary # | ; [[EVOLVE]]: New summary #239: Cinacalcet in ESRD | ||
; [[ADJUST-PE]]: Updated guidelines. | ; [[ADJUST-PE]]: Updated guidelines. | ||
==September 2015== | ==September 2015== | ||
; [[COMET-ICE]]: New summary # | ; [[COMET-ICE]]: New summary #238: Preop coronary revascularization if stable CAD | ||
; [[CARP]]: New summary # | ; [[CARP]]: New summary #237: Preop coronary revascularization if stable CAD | ||
; [[ODYSSEY LONG TERM]]: New summary # | ; [[ODYSSEY LONG TERM]]: New summary #236: PCSK9 inhibitor alirocumab for HLD | ||
; [[Stopping Statins at the End of Life]]: New summary # | ; [[Stopping Statins at the End of Life]]: New summary #235: Palliative statin discontinuation | ||
; JGME Editorial: [http://bit.ly/1UrutR1 Read all about Wiki Journal Club], the website that powers the Journal Club app | ; JGME Editorial: [http://bit.ly/1UrutR1 Read all about Wiki Journal Club], the website that powers the Journal Club app | ||
==August 2015== | ==August 2015== | ||
; [[FLAME (Stroke)]]: New summary # | ; [[FLAME (Stroke)]]: New summary #234: SSRI after CVA for motor recovery | ||
; [[ECST]]: New summary # | ; [[ECST]]: New summary #233: CEA in symptomatic carotid stenosis | ||
; [[ACT]]: New summary # | ; [[ACT]]: New summary #232: Acetylcysteine with IV contrast | ||
; [[PARTNER B]]: Added 5 year follow-up outcomes | ; [[PARTNER B]]: Added 5 year follow-up outcomes | ||
| Line 603: | Line 603: | ||
==July 2015== | ==July 2015== | ||
; [[BRIDGE]]: New summary # | ; [[BRIDGE]]: New summary #231: LMWH bridging for surgery in AF | ||
; [[PREPIC 2]]: New summary # | ; [[PREPIC 2]]: New summary #230: IVC filters for high-risk PE | ||
; [[ASCEND]]: Added new IPF guidelines | ; [[ASCEND]]: Added new IPF guidelines | ||
; [[BRIM-3]]: New summary # | ; [[BRIM-3]]: New summary #229: Vemurafenib in BRAF V600+ melanoma | ||
; Welcome to our new associate editors! | ; Welcome to our new associate editors! | ||
| Line 617: | Line 617: | ||
==June 2015== | ==June 2015== | ||
; [[CHARM-Preserved]]: New summary # | ; [[CHARM-Preserved]]: New summary #228: ARBs in HFpEF | ||
; [[COGENT]] | ; [[COGENT]] | ||
: Added systematic review and expanded criticisms | : Added systematic review and expanded criticisms | ||
; [[WOEST]]: New summary # | ; [[WOEST]]: New summary #227: Clopidogrel ± ASA after PCI if on OAC | ||
; Welcome to our first associate editor! | ; Welcome to our first associate editor! | ||
: Lily Zhou, MD from University of Ottawa is joining the WJC team as Associate Editor of Neurology. | : Lily Zhou, MD from University of Ottawa is joining the WJC team as Associate Editor of Neurology. | ||
; [[IMPROVE-IT]]: New summary # | ; [[IMPROVE-IT]]: New summary #226: Ezetimibe+simvastatin after ACS | ||
; Welcome to our first deputy editor! | ; Welcome to our first deputy editor! | ||
| Line 639: | Line 639: | ||
==May 2015== | ==May 2015== | ||
; [[ADJUST-PE]]: New summary # | ; [[ADJUST-PE]]: New summary #225: Age-adjusted D-dimer for PE | ||
; [[WISDOM]]: New summary # | ; [[WISDOM]]: New summary #224: ICS withdrawal in COPD | ||
; [[MR RESCUE]]: New summary # | ; [[MR RESCUE]]: New summary #223: Thrombectomy vs. standard care in stroke | ||
==April 2015== | ==April 2015== | ||
; [[Can-SAD]]: New summary # | ; [[Can-SAD]]: New summary #222: Light therapy vs. SSRI for SAD | ||
; Technical Update | ; Technical Update | ||
| Line 653: | Line 653: | ||
; Society of General Internal Medicine conference in Toronto: Come say hello and check out our poster (''Journal Club mobile app usage in developing and developed countries'') on Thursday, April 23 at 11:30AM at poster session #2! | ; Society of General Internal Medicine conference in Toronto: Come say hello and check out our poster (''Journal Club mobile app usage in developing and developed countries'') on Thursday, April 23 at 11:30AM at poster session #2! | ||
; [[HYVET]]: New summary # | ; [[HYVET]]: New summary #221: Elderly HTN treatment | ||
==March 2015== | ==March 2015== | ||
; [[ATN]]: New summary # | ; [[ATN]]: New summary #220: RRT intensity in ATN | ||
; [[ASCEND]]: Updated to include detailed discussion of survival endpoints, with attention to progression-free survival and overall survival. | ; [[ASCEND]]: Updated to include detailed discussion of survival endpoints, with attention to progression-free survival and overall survival. | ||
; [[BASALT]]: New summary # | ; [[BASALT]]: New summary #219: Symptom-based asthma therapy | ||
; [[HS troponin-T to rule out MI]]: New summary # | ; [[HS troponin-T to rule out MI]]: New summary #218: High sensitivity troponin for acute chest pain | ||
; [[CYCLOPS]]: New summary # | ; [[CYCLOPS]]: New summary #217: Pulse cyclophosphamide for ANCA vasculitis | ||
; [[StiL]]: Updated to mention the ongoing [[ECOG 2408]] study of maintenance rituximab +/- lenalidomide. | ; [[StiL]]: Updated to mention the ongoing [[ECOG 2408]] study of maintenance rituximab +/- lenalidomide. | ||
==February 2015== | ==February 2015== | ||
; [[ELITE-Symphony]]: New summary # | ; [[ELITE-Symphony]]: New summary #216: Immunosuppression after kidney transplant | ||
; [[ORIGIN n-3 Fatty Acids]]: New summary # | ; [[ORIGIN n-3 Fatty Acids]]: New summary #215: Fish oil for high-risk CVD | ||
; [[HPS2-THRIVE]]: New summary # | ; [[HPS2-THRIVE]]: New summary #214: Niacin in atherosclerotic disease | ||
==January 2015== | ==January 2015== | ||
; [[TALC]]: New summary # | ; [[TALC]]: New summary #213: Tiotropium vs. others in asthma | ||
; [[Age Trial]]: New summary # | ; [[Age Trial]]: New summary #212: Mammograms for 40-49 year old women | ||
; [[STAMPEDE]]: New summary # | ; [[STAMPEDE]]: New summary #211: Gastric bypass vs. medical therapy for T2DM | ||
; [[Cytisine for Smoking Cessation]]: New summary # | ; [[Cytisine for Smoking Cessation]]: New summary #210: Cytisine vs. NRT for tobacco abuse | ||
==December 2014== | ==December 2014== | ||
; [[VALENCE]]: New summary # | ; [[VALENCE]]: New summary #209: Sofosbuvir+ribavirin for HCV genotypes 2 or 3 | ||
; [[TRISS]]: New summary # | ; [[TRISS]]: New summary #208: Transfusion thresholds in sepsis | ||
; [[Lo-Coco 2013]]: New summary # | ; [[Lo-Coco 2013]]: New summary #207: ATRA-ATO vs. ATRA-chemotherapy in APL | ||
==November 2014== | ==November 2014== | ||
; [[BeSt]]: Updated ACR RA guidelines | ; [[BeSt]]: Updated ACR RA guidelines | ||
; [[FEAST]]: New summary # | ; [[FEAST]]: New summary #206: Fluid resuscitation in Sub-Saharan Africa | ||
; [[DAPT]]: New summary # | ; [[DAPT]]: New summary #205: Aspirin/clopidogrel duration after PCI | ||
; [[NA-ACCORD]]: New summary # | ; [[NA-ACCORD]]: New summary #204: Early vs. delayed ART in HIV | ||
; [[AZT Trial]], [[HPTN 052]], [[IPrEx]]: Updated HIV treatment and prevention guidelines | ; [[AZT Trial]], [[HPTN 052]], [[IPrEx]]: Updated HIV treatment and prevention guidelines | ||
; [[ARISE]]: New summary # | ; [[ARISE]]: New summary #203: EGDT vs. usual care in sepsis | ||
==October 2014== | ==October 2014== | ||
| Line 709: | Line 709: | ||
; [[ALBIOS]], [[SAFE]]: Surviving Sepsis Campaign guidelines have been added. (These guidelines have not yet been updated to reflect the results of the [[CRISTAL]] study.) | ; [[ALBIOS]], [[SAFE]]: Surviving Sepsis Campaign guidelines have been added. (These guidelines have not yet been updated to reflect the results of the [[CRISTAL]] study.) | ||
; [[CHARISMA]]: New summary # | ; [[CHARISMA]]: New summary #202: Aspirin/clopidogrel vs. aspirin for CV prevention | ||
; [[CATT]]: New summary # | ; [[CATT]]: New summary #201: Ranibizumab vs. bevacizumab for macular degeneration | ||
; [[CHOICE]]: New summary # | ; [[CHOICE]]: New summary #200: Free long-acting reversible contraception in teens | ||
; [[CheckMate-003]]: New summary # | ; [[CheckMate-003]]: New summary #199: Nivolumab in solid tumors | ||
==September 2014== | ==September 2014== | ||
; [[COMMIT]], [[CURE]], [[ESSENCE]], [[GISSI-3]], [[GUSTO]], [[ISIS-2]], [[MIRACL]], [[PLATO]], [[PROVE IT-TIMI 22]], [[SAVE]], [[TRITON-TIMI 38]], [[VA Cooperative Study]], and [[VALIANT]]: Updated NSTE-ACS guidelines | ; [[COMMIT]], [[CURE]], [[ESSENCE]], [[GISSI-3]], [[GUSTO]], [[ISIS-2]], [[MIRACL]], [[PLATO]], [[PROVE IT-TIMI 22]], [[SAVE]], [[TRITON-TIMI 38]], [[VA Cooperative Study]], and [[VALIANT]]: Updated NSTE-ACS guidelines | ||
; [[GUSTO]]: New summary # | ; [[GUSTO]]: New summary #198: tPA in ACS | ||
; [[Hungarian Prenatal Vitamin Trial]]: New summary # | ; [[Hungarian Prenatal Vitamin Trial]]: New summary #197: Perinatal vitamins to prevent neural tube defects | ||
; [[PARADIGM-HF]]: New summary # | ; [[PARADIGM-HF]]: New summary #196: ARNI vs. enalapril in HFrEF | ||
==August 2014== | ==August 2014== | ||
; [[CHARM-Added]]: New summary # | ; [[CHARM-Added]]: New summary #195: ARB plus ACE-I in HF | ||
; [[ACCORD BP]]: New summary # | ; [[ACCORD BP]]: New summary #194: Intensive BP control in T2DM | ||
; [[COMMIT]]: Update: ACS guidelines | ; [[COMMIT]]: Update: ACS guidelines | ||
; [[VASST]]: New summary # | ; [[VASST]]: New summary #193: Vasopressin in septic shock | ||
; Taking the boards!: August additions coming in the second half of the month. | ; Taking the boards!: August additions coming in the second half of the month. | ||
| Line 741: | Line 741: | ||
==July 2014== | ==July 2014== | ||
; [[ASCEND (IPF)]]: New summary # | ; [[ASCEND (IPF)]]: New summary #192: Pirfenidone in IPF | ||
; [[CRISTAL]]: New summary # | ; [[CRISTAL]]: New summary #191: Colloids vs. crystalloids in shock | ||
; [[Prednisolone in Severe Alcoholic Hepatitis]] and [[Pentoxifylline in Severe Alcoholic Hepatitis]]: Update: Added AASLD/ACG guidelines | ; [[Prednisolone in Severe Alcoholic Hepatitis]] and [[Pentoxifylline in Severe Alcoholic Hepatitis]]: Update: Added AASLD/ACG guidelines | ||
; [[SONIC]]: New summary # | ; [[SONIC]]: New summary #190: Infliximab ± azathioprine induction in Crohn disease | ||
; [[LESS]]: New summary # | ; [[LESS]]: New summary #189: Epidural steroids in spinal stenosis | ||
; [[ASCEND]]: New summary # | ; [[ASCEND]]: New summary #188: Pirfenidone in IPF | ||
==June 2014== | ==June 2014== | ||
; [[RED-HF]]: New summary # | ; [[RED-HF]]: New summary #187: Darbepoetin in HFrEF | ||
; [[ORBIT-AF]]: New summary # | ; [[ORBIT-AF]]: New summary #186: ASA/warfarin vs. warfarin in AF | ||
; [[SWOG 8949]]: New summary # | ; [[SWOG 8949]]: New summary #185: Cytoreductive nephrectomy in metastatic RCC | ||
; [[A-HeFT]], [[CARRESS-HF]], [[COMET]], [[CONSENSUS]], [[COPERNICUS]], [[CORONA]], [[DEFINITE]], [[DIG]], [[DOSE]], [[EMPHASIS-HF]], [[EPHESUS]], [[ESCAPE]], [[EVEREST-Outcomes]], [[MADIT-CRT]], [[MADIT-II]], [[MERIT-HF]], [[RALES]], [[SAVE]], [[SCD-HeFT]], [[SOLVD]], [[STICH]], [[V-HeFT]], [[Val-HeFT]]: Updated HF guidelines | ; [[A-HeFT]], [[CARRESS-HF]], [[COMET]], [[CONSENSUS]], [[COPERNICUS]], [[CORONA]], [[DEFINITE]], [[DIG]], [[DOSE]], [[EMPHASIS-HF]], [[EPHESUS]], [[ESCAPE]], [[EVEREST-Outcomes]], [[MADIT-CRT]], [[MADIT-II]], [[MERIT-HF]], [[RALES]], [[SAVE]], [[SCD-HeFT]], [[SOLVD]], [[STICH]], [[V-HeFT]], [[Val-HeFT]]: Updated HF guidelines | ||
; [[StiL]]: New summary # | ; [[StiL]]: New summary #184: BR vs. R-CHOP for indolent lymphomas | ||
==May 2014== | ==May 2014== | ||
; [[PLACIDE]]: New summary # | ; [[PLACIDE]]: New summary #183: Probiotics to prevent CDAD | ||
; [[VA-NEPHRON D]]: New summary # | ; [[VA-NEPHRON D]]: New summary #182: ACE+ARB in DM nephropathy | ||
; [[RACE II]], [[AFFIRM]], [[ACTIVE A]], [[ACTIVE W]], [[RE-ALIGN]], [[ROCKET AF]], [[AVERROES]], [[ARISTOTLE]], [[RE-LY]]: Updated AF guidelines | ; [[RACE II]], [[AFFIRM]], [[ACTIVE A]], [[ACTIVE W]], [[RE-ALIGN]], [[ROCKET AF]], [[AVERROES]], [[ARISTOTLE]], [[RE-LY]]: Updated AF guidelines | ||
; [[TOPCAT]]: New summary # | ; [[TOPCAT]]: New summary #181: Spironolactone for HFpEF | ||
; [[ONTARGET]]: New summary # | ; [[ONTARGET]]: New summary #180: Ramipril vs. telmisartan vs. both in CVD, stroke, PAD, or DM | ||
==April 2014== | ==April 2014== | ||
; [[POISE-2 ASA]]: New summary # | ; [[POISE-2 ASA]]: New summary #179: Perioperative ASA | ||
; [[PEITHO]]: New summary # | ; [[PEITHO]]: New summary #178: tPA for submassive PE | ||
; [[SEPSISPAM]]: New summary # | ; [[SEPSISPAM]]: New summary #177: MAP 65-70 vs. 80-85 mmHg in sepsis | ||
; [[MADIT-CRT]]: New summary # | ; [[MADIT-CRT]]: New summary #176: CRT in HFrEF with QRS ≥130 msec and mild symptoms | ||
==March 2014== | ==March 2014== | ||
; [[ALBIOS]]: New summary # | ; [[ALBIOS]]: New summary #175: Daily albumin in severe sepsis | ||
; [[ProCESS]]: New summary # | ; [[ProCESS]]: New summary #174: EGDT in septic shock | ||
; [[TTM]]: New summary # | ; [[TTM]]: New summary #173: 33 vs. 36°C body temperature after cardiac arrest | ||
; [[Rifaximin and Lactulose for HE]]: New summary # | ; [[Rifaximin and Lactulose for HE]]: New summary #172: Rifaximin/lactulose vs. lactulose for acute HE | ||
==February 2014== | ==February 2014== | ||
; [[MOPETT]]: New summary # | ; [[MOPETT]]: New summary #171: Low-dose tPA for submassive PE | ||
; [[PCPT]]: New summary # | ; [[PCPT]]: New summary #170: Finasteride for prostate cancer prophylaxis | ||
; [[MIDA]]: New summary # | ; [[MIDA]]: New summary #169: Early surgery for MR | ||
==January 2014== | ==January 2014== | ||
; [[NOTT]]: New summary # | ; [[NOTT]]: New summary #168: Continuous vs. nocturnal oxygen in COPD | ||
; [[AZT Trial]]: New summary # | ; [[AZT Trial]]: New summary #167: Zidovudine in HIV/AIDS | ||
; [[PARAMOUNT]]: New summary # | ; [[PARAMOUNT]]: New summary #166: Maintenance pemetrexed in lung cancer | ||
; [[UKPDS 34]]: New summary # | ; [[UKPDS 34]]: New summary #165: Metformin in T2DM | ||
; [[ICAP]]: New summary # | ; [[ICAP]]: New summary #164: Colchicine in the first episode of acute pericarditis | ||
==December 2013== | ==December 2013== | ||
; [[Twice-daily RT for SCLC]]: New summary # | ; [[Twice-daily RT for SCLC]]: New summary #163: Twice-daily RT in limited SCLC | ||
; [[PARTNER B]]: New summary # | ; [[PARTNER B]]: New summary #162: TAVI for AS in poor surgical candidates | ||
; [[TNT]]: New summary # | ; [[TNT]]: New summary #161: Atorvastatin in stable CAD | ||
==November 2013== | ==November 2013== | ||
; [[ESPRIT]]: New summary # | ; [[ESPRIT]]: New summary #160: ASA+dipyridamole in secondary stroke prevention | ||
; [[PRAMI]]: New summary # | ; [[PRAMI]]: New summary #159: PCI to high-risk non-infarct arteries in STEMI | ||
; [[SYNTAX]]: Update: Added ACCF/AHA guidelines | ; [[SYNTAX]]: Update: Added ACCF/AHA guidelines | ||
; [[AVERROES]]: New summary # | ; [[AVERROES]]: New summary #158: Apixaban vs. ASA in AF | ||
==October 2013== | ==October 2013== | ||
; [[MAGELLAN]]: New summary # | ; [[MAGELLAN]]: New summary #157: Rivaroxaban vs. LMWH for VTE prophylaxis | ||
; [[RE-ALIGN]]: New summary # | ; [[RE-ALIGN]]: New summary #156: Dabigatran in mechanical heart valves | ||
; [[EXTRA]]: New summary # | ; [[EXTRA]]: New summary #155: Omalizumab in severe allergic asthma | ||
; [[HERA]]: Update: Added follow-up data demonstrating similar efficacy but increased cardiotoxicity of 2 years of trastuzumab compared to 1 year. | ; [[HERA]]: Update: Added follow-up data demonstrating similar efficacy but increased cardiotoxicity of 2 years of trastuzumab compared to 1 year. | ||
; [[ATLAS]]: New summary # | ; [[ATLAS]]: New summary #154: 10y vs. 5y tamoxifen in breast cancer | ||
; [[GI bleeding in ICU patients]]: New summary # | ; [[GI bleeding in ICU patients]]: New summary #153: Risk factors for GI bleeds in ICU patients | ||
==September 2013== | ==September 2013== | ||
; [[REDUCE]]: New summary # | ; [[REDUCE]]: New summary #152: 5d vs. 14d steroids in acute COPD | ||
; [[ASTRAL]]: New summary # | ; [[ASTRAL]]: New summary #151: Revascularization in RAS | ||
; [[METEOR]]: New summary # | ; [[METEOR]]: New summary #150: Surgery vs. PT in OA with meniscal tear | ||
; [[Look AHEAD]]: New summary # | ; [[Look AHEAD]]: New summary #149: Weight loss and exercise in T2DM | ||
; [[PLATO]]: New summary # | ; [[PLATO]]: New summary #148: Ticagrelor vs. clopidogrel in ACS | ||
; [[OSCILLATE]]: New summary # | ; [[OSCILLATE]]: New summary #147: High-frequency oscillatory vent in early ARDS | ||
; [[STAR-D]]: New summary # | ; [[STAR-D]]: New summary #146: Tiered approach for depression | ||
==August 2013== | ==August 2013== | ||
; [[LoDoCo]]: New summary # | ; [[LoDoCo]]: New summary #145: Colchicine for stable CAD | ||
; [[AMPLIFY]]: New summary # | ; [[AMPLIFY]]: New summary #144: Apixaban vs. warfarin in VTE | ||
; [[NETT]]: New summary # | ; [[NETT]]: New summary #143: Lung volume reduction in COPD | ||
; [[CSG Captopril Trial]]: New summary # | ; [[CSG Captopril Trial]]: New summary #142: Captopril in T1DM nephropathy | ||
; [[4S]]: New summary # | ; [[4S]]: New summary #141: Simvastatin in stable CAD | ||
; [[ASPIRE]]: New summary # | ; [[ASPIRE]]: New summary #140: Aspirin after VTE treatment | ||
; [[Daily ICU Sedation Holidays]]: New summary # | ; [[Daily ICU Sedation Holidays]]: New summary #139: Scheduled daily sedation holidays in intubated patients | ||
==July 2013== | ==July 2013== | ||
; [[Duct Tape for Treatment of the Common Wart]]: New summary # | ; [[Duct Tape for Treatment of the Common Wart]]: New summary #138: Duct tape vs. cryotherapy for warts | ||
; [[EINSTEIN-PE]]: New summary # | ; [[EINSTEIN-PE]]: New summary #137: Rivaroxaban vs. warfarin in PE | ||
; [[WHI]]: New summary # | ; [[WHI]]: New summary #136: Postmenopausal estrogen/progesterone | ||
; [[CHANCE]]: New summary # | ; [[CHANCE]]: New summary #135: ASA/clopidogrel vs. ASA in TIA/stroke | ||
; [[CRASH-2]]: New summary # | ; [[CRASH-2]]: New summary #134: Tranexamic acid in trauma | ||
; [[NCDS]]: New summary # | ; [[NCDS]]: New summary #133: Dialysis prescriptions in ESRD | ||
==June 2013== | ==June 2013== | ||
; [[BARI 2D]]: New summary # | ; [[BARI 2D]]: New summary #132: CABG/PCI vs. OMT in diabetes with CAD | ||
; [[ARISTOTLE]]: New summary # | ; [[ARISTOTLE]]: New summary #131: Apixaban vs. warfarin in AF | ||
; [[ESCAPE]]: New summary # | ; [[ESCAPE]]: New summary #130: PA catheters in acute HF management | ||
; [[PROSEVA]]: New summary # | ; [[PROSEVA]]: New summary #129: Prone ventilation in ARDS | ||
; [[PREDIMED]]: New summary # | ; [[PREDIMED]]: New summary #128: Mediterranean diet in CVD prevention | ||
; [[EVEREST-Outcomes]]: New summary # | ; [[EVEREST-Outcomes]]: New summary #127: Tolvaptan in acute HF in HFrEF | ||
; [[ACURASYS]]: New summary # | ; [[ACURASYS]]: New summary #126: Cisatracurium in ARDS | ||
; [[DOSE]]: New summary # | ; [[DOSE]]: New summary #125: Diuretic dosing in acute HF | ||
; [[ACCOMPLISH]]: New summary # | ; [[ACCOMPLISH]]: New summary #124: Benazepril/amlodipine vs. benazepril/HCTZ in HTN | ||
==May 2013== | ==May 2013== | ||
; [[CARRESS-HF]]: New summary # | ; [[CARRESS-HF]]: New summary #123: Ultrafiltration in decompensated HF | ||
; [[COMMIT]]: New summary # | ; [[COMMIT]]: New summary #122: Metoprolol in acute MI | ||
; [[RESPECT]]: New summary # | ; [[RESPECT]]: New summary #121: PFO closure in cryptogenic stroke | ||
; [[ESSENCE]]: New summary # | ; [[ESSENCE]]: New summary #120: LMWH vs. UFH in UA/NSTEMI | ||
; [[ACTIVE W]]: New summary # | ; [[ACTIVE W]]: New summary #119: ASA/clopidogrel vs. warfarin in AF | ||
; [[AMPLIFY-EXT]]: New summary # | ; [[AMPLIFY-EXT]]: New summary #118: Apixaban after VTE treatment | ||
==April 2013== | ==April 2013== | ||
; [[TRITON-TIMI 38]]: New summary # | ; [[TRITON-TIMI 38]]: New summary #117: Prasugrel vs. clopidogrel in ACS | ||
; [[MATCH]]: New summary # | ; [[MATCH]]: New summary #116: ASA/clopidogrel vs. clopidogrel in stroke | ||
; [[ROCKET AF]]: New summary # | ; [[ROCKET AF]]: New summary #115: Rivaroxaban vs. warfarin in AF | ||
; [[TRICC]]: Update: Added transfusion guidelines | ; [[TRICC]]: Update: Added transfusion guidelines | ||
; [[PROVE IT-TIMI 22]]: New summary # | ; [[PROVE IT-TIMI 22]]: New summary #114: Pravastatin vs. atorvastatin after ACS | ||
; [[EMILIA]]: New summary # | ; [[EMILIA]]: New summary #113: T-DM1 in metastatic breast cancer | ||
==March 2013== | ==March 2013== | ||
; [[COMET]]: Update: Added criticisms regarding dosage target in metoprolol control arm, as well as choosing metoprolol tartrate rather than standard-of-care metoprolol succinate. | ; [[COMET]]: Update: Added criticisms regarding dosage target in metoprolol control arm, as well as choosing metoprolol tartrate rather than standard-of-care metoprolol succinate. | ||
; [[ATLAS ACS-2, TIMI 51]]: New summary # | ; [[ATLAS ACS-2, TIMI 51]]: New summary #112: Rivaroxaban after ACS | ||
; [[WARFASA]]: New summary # | ; [[WARFASA]]: New summary #111: Aspirin after VTE treatment | ||
==February 2013== | ==February 2013== | ||
; [[Annane Trial]]: New summary # | ; [[Annane Trial]]: New summary #110: Corticosteroids in septic shock | ||
; [[RAVE]]: New summary # | ; [[RAVE]]: New summary #109: Rituximab vs. cyclophosphamide in ANCA-associated vasculitis | ||
; [[IPrEx]]: New summary # | ; [[IPrEx]]: New summary #108: ART in primary HIV prevention | ||
; [[Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile]]: New summary # | ; [[Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile]]: New summary #107: Fecal transplant in C. difficile | ||
; [[NSABP B-32]]: New summary # | ; [[NSABP B-32]]: New summary #106: Sentinel LN biopsy in breast cancer | ||
; [[Transfusion Strategies for Acute Upper Gastrointestinal Bleeding]]: New summary # | ; [[Transfusion Strategies for Acute Upper Gastrointestinal Bleeding]]: New summary #105: Transfusion thresholds in UGIB | ||
==January 2013== | ==January 2013== | ||
; [[Rivers Trial]]: Updates: More on the disagreement over using transfusion to hematocrit >30% for maintaining ScvO<sub>2</sub>, when studies like [[TRICC]] support a more restrictive transfusion strategy. Also, added the baseline characteristics of study participants. | ; [[Rivers Trial]]: Updates: More on the disagreement over using transfusion to hematocrit >30% for maintaining ScvO<sub>2</sub>, when studies like [[TRICC]] support a more restrictive transfusion strategy. Also, added the baseline characteristics of study participants. | ||
; [[Yang-Tobin Study]]: New summary # | ; [[Yang-Tobin Study]]: New summary #104: RSBI for predicting weaning | ||
; [[RENAAL]]: New summary # | ; [[RENAAL]]: New summary #103: ARBs in diabetic nephropathy | ||
; [[CLOSURE I]]: New summary # | ; [[CLOSURE I]]: New summary #102: PFO closure in cryptogenic stroke | ||
==December 2012== | ==December 2012== | ||
; [[STICH]]: New summary # | ; [[STICH]]: New summary #101: CABG in ischemic HFrEF | ||
; [[CURE]]: New summary # | ; [[CURE]]: New summary #100: Clopidogrel in UA/NSTEMI | ||
; [[CAST I]]: New summary # | ; [[CAST I]]: New summary #99: Antiarrhythmics post-MI | ||
; [[V-HeFT]]: New summary # | ; [[V-HeFT]]: New summary #98: ISDN/hydralazine in HFrEF | ||
==November 2012== | ==November 2012== | ||
; [[PRoFESS]]: New summary # | ; [[PRoFESS]]: New summary #97: ASA-dipyridamole vs. clopidogrel in stroke | ||
; [[IRIS]]: New summary # | ; [[IRIS]]: New summary #96: Imatinib vs. IFNα/cytarabine in CML | ||
; [[FAME 2]]: New summary # | ; [[FAME 2]]: New summary #95: FFR-guided PCI vs. OMT in CAD | ||
; [[Moseley Trial]]: New summary # | ; [[Moseley Trial]]: New summary #94: Arthroscopy in knee OA | ||
==October 2012== | ==October 2012== | ||
; [[NSABP P-1]]: New summary # | ; [[NSABP P-1]]: New summary #93: Tamoxifen in breast cancer prevention | ||
; [[HPTN 052]]: New summary # | ; [[HPTN 052]]: New summary #92: Early ART in HIV | ||
; [[FAME]]: New summary # | ; [[FAME]]: New summary #91: FFR-guided PCI in stable CAD | ||
; [[NLST]]: New summary # | ; [[NLST]]: New summary #90: CT vs. CXR in lung cancer screening | ||
; [[IDEAL]]: New summary # | ; [[IDEAL]]: New summary #89: Early vs. late dialysis in CKD | ||
==September 2012== | ==September 2012== | ||
; [[PROWESS-SHOCK]]: New summary # | ; [[PROWESS-SHOCK]]: New summary #88: Activated protein C in septic shock | ||
; [[PROWESS]]: New summary # | ; [[PROWESS]]: New summary #87: Activated protein C in severe sepsis | ||
==August 2012== | ==August 2012== | ||
; [[STAR]]: New summary # | ; [[STAR]]: New summary #86: Tamoxifen vs. raloxifene in breast cancer prevention | ||
; [[POISE]]: Update: Now reflects a major criticism of the trial, namely the high-doses of long-acting metoprolol used in the immediate preoperative period, which may have led to more strokes and deaths in the metoprolol group | ; [[POISE]]: Update: Now reflects a major criticism of the trial, namely the high-doses of long-acting metoprolol used in the immediate preoperative period, which may have led to more strokes and deaths in the metoprolol group | ||
; [[RE-COVER]]: New summary # | ; [[RE-COVER]]: New summary #85: Dabigatran vs. warfarin in VTE | ||
; [[SMART]]: New summary # | ; [[SMART]]: New summary #84: Salmeterol in asthma | ||
; [[GISSI-3]]: Update: Now reflects the 2004 ACC/AHA recommendation for ACE inhibitors or ARBs in all post-STEMI patients | ; [[GISSI-3]]: Update: Now reflects the 2004 ACC/AHA recommendation for ACE inhibitors or ARBs in all post-STEMI patients | ||
; [[EMPHASIS-HF]]: New summary # | ; [[EMPHASIS-HF]]: New summary #83: Eplerenone in HFrEF | ||
; [[PREVENT TB]]: New summary # | ; [[PREVENT TB]]: New summary #82: Rifapentine/isoniazid in latent TB | ||
==July 2012== | ==July 2012== | ||
; [[CORONA]]: New summary # | ; [[CORONA]]: New summary #81: Rosuvastatin in ischemic HFrEF | ||
; [[CREST]]: Update: Now reflects the 2011 ACC/AHA guidelines on carotid artery stenting | ; [[CREST]]: Update: Now reflects the 2011 ACC/AHA guidelines on carotid artery stenting | ||
| Line 1,016: | Line 1,016: | ||
==June 2012== | ==June 2012== | ||
; [[CATIE]]: New summary # | ; [[CATIE]]: New summary #80: Antipsychotics in schizophrenia | ||
; [[SYNTAX]]: New summary # | ; [[SYNTAX]]: New summary #79: PCI vs. CABG in severe CAD | ||
; [[Early Palliative Care]]: New summary # | ; [[Early Palliative Care]]: New summary #78: Palliative care in NSCLC | ||
; [[JUPITER]]: New summary # | ; [[JUPITER]]: New summary #77: Rosuvastatin for primary CV prevention | ||
; [[SPARCL]]: New summary # | ; [[SPARCL]]: New summary #76: Atorvastatin after stroke | ||
==May 2012== | ==May 2012== | ||
; [[CHOIR]]: New summary # | ; [[CHOIR]]: New summary #75: EPO in CKD with anemia | ||
; [[SADHART]]: New summary # | ; [[SADHART]]: New summary #74: Sertraline for depression post-ACS | ||
==April 2012== | ==April 2012== | ||
; [[SHOCK]]: New summary # | ; [[SHOCK]]: New summary #73: Early PCI/CABG in MI + shock | ||
; [[SOLVD]]: New summary # | ; [[SOLVD]]: New summary #72: Enalapril in moderate-severe HFrEF | ||
; [[DASH]]: New summary # | ; [[DASH]]: New summary #71: DASH diet in HTN | ||
; [[SEDCOM]]: New summary # | ; [[SEDCOM]]: New summary #70: Dexmedetomidine vs. midazolam for sedation | ||
; [[ACTIVE A]]: New summary # | ; [[ACTIVE A]]: New summary #69: ASA/clopidogrel vs. ASA in AF | ||
; [[COGENT]]: New summary # | ; [[COGENT]]: New summary #68: PPI plus clopidogrel in CAD | ||
; [[European Dexamethasone Study]]: New summary # | ; [[European Dexamethasone Study]]: New summary #67: Dexamethasone in meningitis | ||
__NOTOC__ | __NOTOC__ | ||